Methyglyoxal (MGO), an essential endogenous dicarbonyl metabolite, can lead to multiple physiological problems including hyperglycemia, kidney diseases, malignant tumors, beyond its normal concentration range. The glyoxalase system, making MGO maintained at a low level, links glycation to carcinogenesis, growth, metastasis, and cancer chemotherapy. The glyoxalase system comprises glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2), which is often overexpressed in various tumor tissues. However, very little is known about the glyoxalase system in breast cancer and gynecological cancer. In this review, we introduce the role of the glyoxalase system in breast cancer, endometrial cancer, ovarian cancer and cervical cancer, and highlight the potential of the glyoxalase system to be both as a marker for diagnosis and a novel target for antitumor therapy. However, the intrinsic molecular biology and mechanisms of the glyoxalase system in breast cancer and gynecological cancer need further exploration.

Keywords: glyoxalase system, endometrial cancer, methyglyoxal, ovarian cancer, cervical cancer, breast cancer

1. INTRODUCTION

Tumor cells are characterized by uncontrolled growth and proliferation, with an oncometabolic hallmark of favored use of glycolysis for lactate production even under oxygen-rich conditions, referred to as "the Warburg effect" (1–3). This effect is seen as part of metabolic reprogramming in tumors to provide conditions for their proliferation, migration, survival, and drug resistance (3). In fact, the imbalance of energy metabolism is an important driving factor of oncogenesis, with a significant metabolic result being intracellular accumulation of methyglyoxal (MGO). This tends toward causing toxic effects on cells, inhibiting growth and promotion of apoptosis. Increased glyoxalase expression and activity compensate for the accumulation of cytotoxic metabolites in tumor cells. Glyoxalase system, mainly consisting of Glyoxalase 1 (Glo1) and Glyoxalase 2 (Glo2), is a defensive pathway against dicarbonyl stress produced by MGO (4). The formation of MGO increases under conditions of high glycolytic flux, encountered by all cancer cells. When this happens, this detoxification system works and endows tumor cells with adaptive advantage.

Thus, the glyoxalase system is particularly abundant in cancerous cells and this fact has been confirmed by some studies. However, very little is known about the glyoxalase system in gynecological cancer and most work has been done on breast cancer considering female cancers.
Thus, the purpose of this review is to introduce the role of the glyoxalase system in breast cancer and gynecological cancer systematically including endometrial cancer, ovarian cancer and cervical cancer, and highlight the potential to be both as a marker for diagnosis and a novel target for antitumor therapy.

2. METHYGLYOXAL (MGO)

MGO which contains two carbonyl groups and is active in nature, together with glyoxal (GO) and 3-deoxyglucosone (3-DG), are referred to as highly reactive dicarbonyl metabolites (5). Among them, MGO is an important endogenous dicarbonyl metabolite that exists in various tissues and organs in the human body, and will cause multiple physiological problems, including hyperglycemia, kidney diseases and malignant tumors, when it exceeds its normal concentration range (6–9). Dicarbonyl stress, which is abnormal increase in the amount of dicarbonyl metabolites, leads to the increase of protein and DNA modification (10). Dicarbonyl stress can be caused by two mechanisms, including out-of-balance of dicarbonyl metabolites and increased exposure of exogenous dicarboxyls (11).

MGO is produced largely by the degradation of glyceraldehyde-3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP) during glycolysis non-enzymatically (4, 12). It can also be produced during hydrolysis and dephosphorylation of DHAP and G3P (13), lipid peroxidation (14, 15), catabolism of threonine (16), oxidation of acetone catalyzed by cytochrome P4502E1 (17), and autoxidation of glucose and degradation of glycated proteins (18, 19). The likelihood of G3P degrading into MGO is eight times than that of DHAP. However, in cells in situ, the concentration of DHAP is about nine times that of G3P (20). Therefore, both forms of triosephosphates are necessary for the formation of MGO (4).

MGO is attained not only during cell metabolism, but also through exogenous dietary intake; its primary sources are coffee and other types of beverages (21, 22). However, ingested MGO is metabolized and exerts dicarbonyl stress pre-systemically before absorption (23).

MGO is mostly eliminated by the glyoxalase system, with minority being metabolized by aldoketo reductases (AKRs) and aldehyde dehydrogenases (ADHs), which convert it into hydroxyacetone and pyruvate, respectively; thus, forming an enzymatic defense to prevent MGO glycation (24–28). In various human tissues, the capacity of the Glo system to metabolize MGO is 30 times that of AKRs; one exception is the renal medulla, where the expression of AKRs is particularly high (29, 30). In general, MGO is produced during glycolysis and metabolized through the glyoxalase system, at low level in vivo. However, when glycolysis is abnormal or food containing high MGO is consumed for a long time, the load of the scavenging system in the body becomes too heavy. This results in the over-accumulation of MGO in the body. The serious cytotoxicity and tissue damage in MGO-related metabolic disorders are likely caused by the modification of nucleic acids, free amino groups in proteins and lipids induced by a large family of MGO-derived adducts, called advanced glycation end-products (AGEs) (31). MGO interacts with deoxyguanosine, leading mainly to form the imidazopurinone adduct, MGdG (26, 32). MGdG, comprising the majority of MGO nucleotide adducts physiologically, are mutagenic and possibly related to malignant transformation (25). A small amount of 2-(1, R/S-carboxyethyl)-deoxyguanosine (CEDG) is also formed (33). The irreversible interaction of MGO with arginine results in the formation of MG-derived hydroimidazolones (MG-H1, MG-H2, and MG-H3) (34–36), argpyrimidine (37) and tetrahydropyrimidine (THP) (38). MGO can also modify lysine residues to form Ne-(1-carboxyethyl) lysine (CEL) and 1,3-di(N-lysino)-4-methyl-imidazolium (MOLD), although to a much lesser extent than arginine (39). MGO can also react with one lysine and one arginine, leading to the formation of an adduct called MODIC (40). MGO also induces stable lipid modifications (Figure 1).

Additionally, AGEs can bind to the receptor for AGEs (RAGE), mediating signal transduction and stimulating intracellular reactive oxygen species (ROS) generation. Activation of RAGE signaling is related to various cellular changes, including inflammation and oxidative stress, which play a role in carcinogenesis, and increased cell death by apoptosis and anoikis (26, 41–44). Decreased expression of RAGE is associated with the inhibition of tumor development and metastasis (45).

3. GYOXAL (GO)

In addition to MGO, GO is also an endogenous highly reactive dicarboxy metabolites. The formation of GO seems to be inevitable in organism, since they are closely connected with several physiological processes, such as lipid peroxidation and degradation of monosaccharides, saccharide derivatives and glycated proteins (46, 47). Since GO is a potent glycating agent, modification of proteins and nucleotides has been found. GO can react with proteins to form AGE residues directly, with arginine residues being the most reactive protein (48). DNA is also susceptible to glycation by GO, with deoxyguanosine (dg) being the most common modified nucleotide AGEs. GO was responsible for increased mutations and decreased DNA replication. Nearly half of mutations were single-base substitutions with more than 80% occurring at C:G sites. Furthermore, GO was in relation to non-random or hotspot mutation sites (49). Similar to MGO, elevation in GO also leads to dicarboxyl stress, which is associated with various health problems and the modification by GO is regarded as damage to physiological systems. However, this can be suppressed by detoxification of GO, catalysed mainly by the glyoxalase system (47, 50). In most cases, GSH was utilized to convert GO to S-2-hydroxyethylglutathione, mediated by GSH-dependent Glyoxalases, Glo1 and Glo2. In some cases, GO can also be the substrate of Glyoxalase 3 (Glo3), but without any cofactors (51, 52).
4. GLYOXALASE SYSTEM

The glyoxalase system is one of the well-defined associations between glycation and carcinogenesis and progression. It was first introduced by Dakin, Dudley in 1913 (32). This system, existing in the cytoplasm of all human cells, mainly consists of two cooperating enzymes, namely, Glo1 and Glo2. The main duty of the system is to metabolize MGO and other reactive acyclic a-oxoaldehyde metabolites, to maintain them at a low level, thus preventing cell and tissue dysfunction. MGO and glutathione (GSH) produce hemithioacetal through a non-enzymatic reaction. Then hemithioacetal is converted into S-D-lactoylglutathione, under the catalysis of Glo1. Glo2 catalyzes the hydrolysis of S-D-lactoylglutathione to D-lactate, thereby reforming GSH, to achieve detoxification of MGO (53). In this series of reactions, Glo1, as a rate-limiting enzyme, is of vital importance in the detoxification of MGO (Figure 2). There also exists the GSH-independent system involving Glo3 to protect cells from MGO toxicity, besides the GSH-dependent system consisting of Glo1 and Glo2. Glo3 was first identified in the Hsp31 protein from Escherichia coli, which can directly convert MGO into D-lactate in the absence of GSH (54). In recent literature, the DJ-1 proteins from Arabidopsis thaliana and metazoans have also been confirmed to have Glo3 activity like the Hsp31 protein, but they belong to two different subfamilies of the DJ-1 superfamily proteins. In animals, DJ-1 proteins appear to show Glo3 activity and the dysfunction of DJ-1 proteins can make cells sensitive to oxidative stress and cause mitochondrial disorders (54, 55). To date, however, Glo3 remains unidentified in human system. Furthermore, the regulatory mechanisms of Glo3 merit continued study. It is noteworthy that DJ-1 proteins are now considered a deglycase, rather than an alternative glyoxalase (56).

4.1 Glo1

Glo1 is a zinc-dependent metalloenzyme encircled by two identical subunits. It has a molecular mass of 43-48 kDa and is comprised of noncovalent bonds (57, 58). It exists in almost all prokaryotic and eukaryotic organisms, including animals, plants, yeast, bacteria, and protozoa. Furthermore, its widespread distribution reflects its important physiological functions in biological life. Moreover, it has been found that Glo1 has high homology among different species through comparison of amino acid sequences. This implies an evolutionarily conserved function for Glo1. Human Glo1 is located on chromosome 6 at locus 6p21.2, with five introns and six exons. It is often overexpressed in tumor tissues (59–61). The mechanism by which Glo1 expression is regulated is complex. It is controlled by various regulatory elements and that can be altered by the changes in gene expression and post-translational enzymatic modifications (62, 63). Transcriptional regulators of Glo1 include activator protein-2α (AP-2α), early gene 2 factor isoform 4 (E2F4), nuclear transcription factor-κB (NF-κB), activator protein-1 (AP-1), antioxidant response (ARE), metal response (MRE), and insulin response (IRE) elements. Post-translational modifications are achieved through phosphorylation, nitrosylation, and glutathionylation. Among these, Glo1 expression is positively regulated by AP-2α, E2F4, NF-κB and nuclear factor erythroid 2-related factor 2 (Nrf2) by enhancing the Glo1 promoter. For instance, expression is controlled by Nrf2 during stress by binding with AREs (64, 65). In tumor cells, the enhanced expression of Nrf2 leads to increased activity of the enzyme, thereby preventing dicarbonyl stress. Therefore, Nrf2 is often over-activated in hepatocellular carcinoma and thus contributes to increased mortality (66). It has been demonstrated that Nrf2 activators, including sulforaphane and resveratrol, act as Glo1 inducers (67).
Nuclear translocation of Nrf2, which is of vital importance in the activation of Glo1, can be disrupted by the combination of MGOs to Kelch-like ECH-associated protein 1 (Keap1). Based on this principle, MGO inhibitors can help detoxification in cells via the Nrf2/Keap1 pathway by elevating GSH levels and accelerating MGO metabolism (68). In contrast, the expression of Glo1 is also negatively mediated by hypoxia-inducible factor-1α (HIF1α), the receptor for advanced glycation end products (RAGE). Its levels are also impacted by conflict between the NF-κB system activated in inflammation and Nrf2 (69, 70).

Copy number variation (CNV) of the Glo1 gene in the human genome will also allow for increased expression of Glo1 with low-level duplication in the healthy population (71). The Glo1 DNA segment copy number increase was larger among illness affected groups than that in the healthy population with low-level duplication (72). In a study of 225 different types of human tumors, increased Glo1 copy number was discovered in 8% of tumors, with the highest prevalence of Glo1 amplification in breast cancer (22%), followed by sarcomas (17%) and non-small cell lung cancer (11%) (73). The correlation between Glo1 copy number increase assessed by qPCR and poor survival in gastric cancers has been ameliorated (74).

4.2 Glo2
Human Glo2 is another enzyme in the glyoxalase system. It is encoded by the hydroxyacylglutathione gene (HAGH1). Genetic polymorphisms of Glo2 are rare, with HAGH1 being the only the second phenotype expressed (75). It is a binuclear metalloenzyme with a Zn(II) site as the catalytically active site metal ion. By contrast, the Fe(II) site has no influence on the catalytic activity (70). However, the molecular structures of Glo2 share the same overall fold as Zn(II)-dependent metallo-β-lactamases (76). There are two isoforms of Glo2 depending on their localization in cellular compartments. This includes the mitochondrial form with a molecular mass of 33.8 kDa and a cytosolic form with a molecular mass of 29.2 kDa (77). Despite their differences, the two isoforms have identical isoelectric points of 8.3 (78).

Emerging evidence pointed out the novel independent role of this ancient enzyme from that of Glo1 in a possibly nonenzymatic manner in some malignant cells. In Cinzia et al.’s study, Glo2 was involved in the proapoptotic effects of Oleuropein in non-small-cell lung cancer A549 cells (79). Oleuropein led to an increase in mitochondrial Glo2 protein expression levels without enhancing the enzyme’s activity. Conversely, Oleuropein did not affect expression or function of cytosolic Glo2. Through upregulation of mitochondrial Glo2, Oleuropein is able to induce apoptosis in A549 cells which is mediated by the superoxide anion and Akt signaling pathway. In addition, the proapoptotic effect of mGlo2 is related to the interaction with the Bax protein. Even though there is no distinction between the mitochondrial or cytosolic isoforms, this emerging independent role turns out to be opposite in prostate cancer cells, where an antiapoptotic nonenzymatic...
role of Glo2 was identified (80). In prostate cancer cells, this
ancient enzyme is able to stimulate cell proliferation and elude
apoptosis in a mechanism dependent on androgen receptor and
involving the p53-p21 axis (81).

5. BREAST CANCER

Breast cancer is the most common cancer in women worldwide
with an estimated 2.09 million cases and 0.6 million deaths
annually (82). It is a heterologous disease and categorized
accordingly to the so-called intrinsic breast cancer subtypes
employing the expression of estrogen receptor (ER),
progesterone (PR) and human epidermal growth factor
receptor 2 (HER2), together with the frequency of ki-67 (83,
84). Moreover, treatment strategy is designed based on
the expression of receptors and ki-67 (85). The use of anti-
endocrine therapy to downregulate ER signaling is the primary
systemic therapy for ER-positive or PR-positive cases by receptor
mediators such as tamoxifen. Patients with HER2-positive benefit
from monoclonal antibodies directed against this EGF-receptor,
such as trastuzumab and pertuzumab. For triple negative cases,
there is no targeted therapy in routine clinical use, thus, most
patients are treated with chemotherapy (6). However, this
immunohistochemistry-based clinical classification is only a
substitute for gene expression analysis and cannot identify all
internal molecular characteristics (84).

To our knowledge, the first study giving a comprehensive
picture of the role of Glo1 in breast cancer dates back to the 2001,
when A Rulli et al. measured Glo1 specific activity in breast
carcinoma and normal mammary gland tissue (85). Samples
were drawn in the period from 1999 to 2000 of 20 women and
Glo1 was significantly upregulated in human breast cancer cells
and tissues, as shown by both spectrophotometrical assay and
electrophoretic pattern compared with normal counterparts. A
consistent enhanced of Glo1 expression was observed either at
mRNA or protein level in human breast cancer tissues
parallel with pair-matched normal tissue, providing evidence
for a potential role of this enzyme in breast cancer (86–89). In
addition, Glo1 promoted cell proliferation, invasion and
migration and suppressed cell apoptosis. Hence, Glo1
overexpression correlated with aggressive clinicopathological
features including lymph node metastasis, lymphovascular
invasion, tumor grade and TNM stage and was an independent
prognostic factor for clinical outcome of breast cancer patients.
Specifically, patients with Glo1 overexpression had a shorter
overall survival and recurrence-free survival than those with low
Glo1 expression (88, 90). Moreover, knockdown of Glo1
suppressed invasion and migration and promoted apoptosis of
breast cancer cells in vitro (88). These results suggest that Glo1 is
significantly associated with tumorigenesis, metastasis, and poor
prognosis, providing new impetus to the exploring the
expression of Glo1. Additionally, gene expression data
demonstrated that Glo1 mRNA was regulated through a
mechanism involving inflammation (NF-kB) and oxidative
stress (NFE2L2) in malignant breast cells (91). In Guo et al.
study, Glo1 restraint treatment can hinder occurrence and
development of breast cancer cells, adjusted by actuation of
the MAPK signaling pathway and downregulation of
Bcl-2 and MMP-9 (92). However, the intrinsic molecular
biology and mechanisms of breast carcinogenesis remain to be
further elucidated.

Therefore, Glo1 is involved in the regulation of tumorigenesis,
proliferation, migration and survival in breast cancer (93). These
data has supported the role of Glo1 as a potential target for
anticancer drug development, which were indeed confirmed by
some studies. Clinically, a major obstacle in the process of
treating tumor lies in drug resistance. It has been reported in
previous literature that chemotherapeutic resistance, including
doxorubicin, was associated with upregulation of Glo1 (94).
Recent studies on the mechanism of drug resistance of breast
cancer have found that Glo1 inhibitors can reserve drug
resistance of tumor cells. Davies et al. showed that the
thiazolidinedione troglitazone downregulated Glo1 expression,
leading to a regained sensitivity to doxorubicin. Furthermore, it
is also reported that Glo1 abundance could predict the outcome
of radiotherapy and overexpression of Glo1 was associated with a
shorter relapse free survival after receiving radiotherapy (91). It
is reported that more than 50% of all drugs used in tumor
treatment contain either natural origin active principles or
semisynthetic derivatives, thus, there is an urgent need to find
new drugs from bioactive compounds (95). In a recent study, the
influence of resveratrol, curcumin and piperine on Glo1 activity
and expression was assessed in MCF-7 cell. The dose-dependent
inhibitory effects of resveratrol, curcumin and piperine on Glo1
activity were observed after 24 hours of treatment. However, the
expression of Glo1 could be reduced only by curcumin, due to
the possible fact that resveratrol and piperine affect the activity of
Glo1 in a posttranslational manner (96). Similar conclusions
were also obtained to confirm the effect of curcumin on Glo1
(97, 98).

Moreover, distant metastasis would be present in 15% of
patients with breast cancer, and contribute to approximately 90%
of cancer-associated mortality (99). Thus, determining potential
key regulators in the process of cancer metastasis seems to be
increasingly important. According to a recent report, in patients
with stage III–IV breast cancer, Glo1 and PKCα may be
collaboratively involved in cancer progression and patients with
high Glo1 and PKCα expression had worse prognosis (87). In
addition, the Glo1 inhibitor, TLSC702, and the PKCα inhibitor,
aurothiomalate, may serve as novel pharmacological approaches
to manage late-stage breast cancer through suppressing both cell
viability and tumor–sphere formation in MDA–MB–157 and
MDA–MB–468 human basal-like breast cancer cells. However,
there is absence of in vivo studies using TLSC702 or
aurothiomalate, further investigation of the inhibitors is
needed in future.

It is worth noting that in the study of Marie-Julie Nokin et al.,
a tumor-suppressing role of Glo1 in breast cancer cells was
identified for the first time (100, 101). Silencing of Glo1, bearing
a higher level of MGO, promoted tumor growth and metastasis
in vivo and Glo1-depleted breast cancer cells induced a
significant increase in pulmonary tumor burden. A similar role of Glo1 has also been validated in hepatocellular carcinoma and downregulation of Glo1 enhanced tumor growth (102). The mechanism was further revealed that metastasis was associated with the activation of MEK/ERK/SMAD1 cascade in breast cancer cells (101). Moreover, this study investigates therapeutic potential of MG scavengers, including carnosine and aminoguanidine, as promising target in the management of metastatic breast cancer.

In fact, these seemingly contradictory data might be explained by the effect exerted by MGO on cancer cells that is defined by low-dose stimulation and high-dose inhibition of tumor metastasis (103). Thus, it is necessary to determine the MGO concentrations when Glo1 inhibitor applied.

6. ENDOMETRIAL CANCER

Endometrial cancer is the most common gynecological malignancy in the United States, and its related mortality is on the rise (104). Surgical staging system including laparoscopic total hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph-node mapping, has been adopted. Most cases are diagnosed in the early stage of the disease, presenting with vaginal bleeding. Hence, the prognosis is good, with the overall five year survival rate being 90.88% for patients staged as IA using the FIGO 1988 surgical classification (105). However, challenges still remain, including increasing radical disparities in mortality (106).

6.5% of the patients suffered from endometrial cancer are younger than 45 years of age (107). Women of childbearing age prefer to preserve their fertility for future opportunities to give birth, rather than receive the standard surgical treatment of total hysterectomy with bilateral salpingo-oophorectomy, sentinel lymph node mapping and pelvic/para-aortic lymphadenectomy when necessary. Fertility preservation is suitable for young women with stage I, grade I adenocarcinoma. Thus, alternative treatments involving synthetic progestins, including medroxyprogesterone acetate (MPA), are the mainstays of such management. Unfortunately, about 30% of said alternatively treated cases, fail to respond to progestins initially. Although the response rate is approximately 70%, 57% of patients relapse and develop drug resistance (108). In brief, progestin resistance restricts the validity of progestin treatment. Zhang et al. reported that the expression of Glo1 in progestin-resistant Ishikawa cells was increased 2.4-fold higher than that in parental cells. This suggests that Glo1 is related to progestin resistance in endometrial cancer. Further, metformin, an insulin sensitizers, can downregulate Glo1 expression to enhance the response to MPA treatment by blocking PI3K-mTOR activation (109). In another study, metformin sensitizes progestin in endometrial cancer through downregulation of Ten-eleven translocation 1 (TET1), a dioxygenase responsible for transferring 5-methylcytosine into 5-hydroxymethylation and CpG islands enriched in the promoter region of Glo1 are possible target of TET1. Therefore, metformin enhances progestin sensitivity underlying the potential mechanism of TET1/5hmC/GLOI signaling pathway (110). Therefore, the combination of metformin and MPA is likely an effective strategy for conservative treatments of endometrial cancer and accumulating evidence suggests that Glo1 is a potential target gene of metformin.

Traditionally, chemotherapy has been extensively used an adjuvant treatment for endometrial cancer. However, in this case, the initial reaction of malignant endometrial tumor cells to chemotherapy turns refractory over time, resulting in high rates of chemoresistance (111). There is an urgent need to address this issue. Considering that obesity and diabetes are risk factors for the incidence of endometrial cancer, it may be partly caused by metabolic disorders (112). Metformin, a well-tolerated biguanide drug, has been implicated in the treatment of various tumors, including endometrial cancer. According to research, compared with cisplatin and paclitaxel alone, as the first-line chemotherapeutics for endometrial cancer therapy, the administration of metformin strongly inhibits the proliferative activity of tumor cells (113). Further investigation of the possible molecular mechanism by which metformin enhances, chemotherapeutic drug-mediated cytotoxicity, revealed that increasing the dose of metformin reduces the expression of Glo1 protein. This indicates that metformin can enhance sensitivity to chemotherapeutic drugs in endometrial cancer by downregulating Glo1 expression. In fact, since overexpression is present in various cancers, aberrant expression of Glo1 is involved in drug resistance (85, 114). Thus, the expression pattern of Glo1 may play an important role in cancer proliferation.

Previous research has shown that the expression of Glo1 is upregulated in a variety of human malignancies, including melanoma, gastric cancer, pancreatic cancer, breast cancer, renal cancer, prostate cancer (5, 74, 80, 88, 115, 116). This result is similar to that of Sakamoto, who determined that Glo1 enzyme activity was elevated in all 38 human cancer cell lines compared to normal tissue samples (117). High expression of Glo1 is permissive for the survival of tumors with a relatively high flux of MGO formation. Furthermore, elevated Glo1 expression is associated with multidrug resistance in cancer chemotherapy (59). Davies et al. treated doxorubicin-resistant K562 leukemia cells with troglitazone, an insulin sensitizer, and drug resistance was reversed by downregulating the expression of Glo1 (114). The key to inhibiting Glo1 expression to reverse drug resistance lies in promoting cell apoptosis, and there are several potential mechanisms, as described below, although the exact mechanisms are not clear yet. Inhibiting Glo1 expression can result in MGO accumulation to cytotoxic levels that then cause cell death by apoptosis. Therefore, this mechanism is likely caused by increased intracellular MGO, as induced by antitumor agents. On the one hand, MGO has been proven to simulate the release of cytochrome C from mitochondria and subsequently induce apoptosis by modifying the mitochondrial permeability transition pore (118). In addition, nucleic acids and free amino groups in anti-apoptotic proteins can be modified by MGO, thus potentially leading to apoptosis. For example, MGO may enhance the anti-apoptotic activity of Hsp27 by inhibiting...
the activation of caspase-3 and caspase-9 mediated by cytochrome c to protect cancer tumors from cell deaths (119–121). In this way, compared to cells with low endogenous MGO-modified Hsp27, lung cancer cells with high expression of MGO-modified Hsp27 are resistant to cisplatin-induced apoptosis (119). Similarly, MGO-modified Hsp27 has been found in melanoma, lung, and gastrointestinal tumors (119, 120). Accordingly, Glo1 inhibitors can induce the activation of p38 and JNK stress-activated kinases; which activates downstream caspases in Glo1-overexpressing tumor cells to induce apoptosis (117, 122). Godbout et al. found that the cisplatin-induced apoptosis of myeloma cells was promoted by MGO through activation of protein kinase Ca (118). Although these results suggest that MGO plays an important role in inhibiting the expression of Glo1, the exact mechanism requires further exploration. According to the literature in the field of endometrial cancer, we found that metformin was an effective inhibitor of Glo1 that had antitumor activity, although the intrinsic mechanism needs to be explored further.

7. OVARIAN CANCER

Although the incidence of ovarian cancer is not as high as that of other cancers, such as endometrial cancer, it is the most lethal of the female reproductive tract malignancies in the United States (123). Owing to a lack of suitable screening methods, diagnosis is possible only at an advanced stage for most patients; however, at this stage, the tumor has usually spread to the peritoneal cavity and upper abdominal organs, leading to poor prognosis (124). The standard treatment for ovarian cancer focuses on cytoreductive surgery followed by postoperative adjuvant chemotherapy (125). At present, the five-year survival rate is approximately 47% even in countries with advanced medical technology such as the United States and Canada, mainly due to late diagnosis, recurrence, and chemo-resistance (126).

Currently, the gold standard for diagnosis relies on pathological biopsy, and early screening methods are limited. Some existing biomarkers such as carbohydrate antigen 125, human epididymis protein 4, may be helpful in screening, but the wide application is hampered by their poor sensitivity or specificity. Thus, it is very necessary to identify novel biomarkers for early detection of ovarian cancer. Considering the fact that blockade of the RAGE-ligand pathway represents a novel target for some cancer therapy (127–130), the researchers have further investigated the role of RAGE in ovarian cancer development. Data showed that RAGE expression was upregulated in ovarian cancer tissue compared with matched normal tissue (131). Moreover, a significant relation between high RAGE expression levels and poor clinicopathological features, such as tumor size, depth of stromal invasion, lymphovascular invasion and stage of tumor was observed, suggesting an important role of RAGE in ovarian cancer progression. In the present study, the area under the curve value was 0.86 for RAGE, implying a relatively high sensitivity and specificity for the RAGE mRNA level to differentiate between malignant and non-malignant tissues. Thus, the overexpression of RAGE may be a potential biomarker for diagnosis of ovarian cancer. Consistent with our results, Poljicanin et al. also came to a similar conclusion (132).

In addition, most ovarian cancers originate from a single layer of surface epithelial cells (OSE), accounting for only a small proportion of the total ovarian mass (133). Apparently, normal OSE cells from women with a family history of ovarian cancer and breast cancer are different from women without phenotypic and/or genotypic family history. Smith Beckerman examined the proteomes of both SV-40-transformed FH-OSE cell lines and control OSE lines. Expression of several proteins appeared to be elevated in the FH-OSE cells, including Glo1, suggesting that high expression of Glo1 is related to the occurrence and progression of ovarian cancer (134). Although ovarian tumors at an early stage are highly curable (135), more than 70% of cases are not diagnosed until the tumor has progressed to advanced stages (136), reflecting the potential high morbidity and mortality caused by presentation with advanced-stage disease. Monica Brown Jones revealed a high degree of overexpression of Glo1 in invasive ovarian cancers compared with the low malignant potential ovarian tumors. Her work combined the technique of laser capture microdissection of epithelial tumor cells in human tissue specimens with two-dimensional gel electrophoresis (137). Results suggest that Glo1 may be a potential marker for early detection and therapeutic targets unique to the invasive phenotype.

The exact mechanisms of Glo1 in the ovarian cancer remain unknown and Glo1 may be used as a therapeutic target in the future. Thus, more investigations are encouraged to provide more reliable data.

8. CERVICAL CANCER

The cause of cervical cancer is clear, being mostly associated with the sexually transmitted persistent human papilloma virus infection. The key to intervention lies in primary and secondary prevention (138). Standard treatment after diagnosis consists of surgical resection and concurrent chemoradiation according to the stage of the tumor and clinicopathologic risk factors. Although the number of cervical cancer cases has decreased in developed countries in the past decade, its incidence has continued to rise rapidly in developing countries (139). According to the latest cancer statistics, cervical cancer is ranked fourth in terms of morbidity and is one of the main causes of death for women with malignant tumors, with approximately 604,000 new confirmed cases as well as 342,000 death cases worldwide in 2020 (140). Thus, cervical cancer still represents a major public health problem globally and there is an urgent need for improved therapeutic options to reduce the burden.

In recent years, more and more researchers have paid attention to phyto chemicals present in various plants, with properties being time tested usage and low toxicity. Hence, Raj Kumar et al. assessed pharmacological action of the inhibitor of
Nrf-2, Galangin, an active component of galangal, present in many traditional medicines. Previous reports have confirmed that Galangin contributes to health ranging from antioxidant effect to synergistics anticancer effects with other medicine (141, 142). In the present study, Galangin can modulate Nrf-2 levels to induce cell death and inhibit metastatic potential in human cervical cancer cell line (HeLa) cells in vitro. This occurs by downregulating the expression of Glo1 in concentration dependent manner and increasing the damage caused by MGO and oxidative stress (143). In fact, the cytotoxicity of Galangin has been proven in other cancer cell lines, such as human colon cancer cells, melanoma cells, and renal carcinoma cells (144–146). However, little research has been conducted on the role of glyoxalases in cervical cancer. More research is needed along these lines to inform future applications.

9. CONCLUDING REMARKS

Glyoxalases are often overexpressed in various tumor tissues and they play an important role in tumor proliferation, migration, survival, and drug resistance. In this review, we introduce the role of the glyoxalase system in breast cancer and gynecological cancer, including endometrial cancer, ovarian cancer and cervical cancer. The main function of the glyoxalase system is to metabolize MGO and other reactive acyclic a-oxoaldehyde metabolites, to maintain them at a low level to prevent cell and tissue dysfunction. In most cases, Glo1 overexpression correlated with aggressive clinicopathological features and poor prognosis. However, a tumor-suppressing role of Glo1 has also been identified in breast cancer cells. Due to the possible effect exerted by MGO on cancer cells that is defined by low-dose stimulation and high-dose inhibition of tumor metastasis, it is necessary to determine the MGO concentrations when Glo1 inhibitor applied. These data demonstrated the potential of the glyoxalase system to be as a target for diagnosis and suggested that agents designed to regulate Glo1 may provide a promising method to cancer prevention and therapy. However, the intrinsic molecular biology and mechanisms of the glyoxalase system in breast cancer and gynecological cancer remain to be further elucidated. Therefore, further research is needed in this area.

AUTHOR CONTRIBUTIONS

Conceptualization, JYW; methodology, XY; investigation, ZW; writing—original draft preparation, JYW; writing—review and editing, JYW; visualization, ZW; supervision, JLW; funding acquisition, JLW. All authors have read and agreed to the published version of the manuscript.

FUNDING

This research was funded by the National Key Technology R&D Program of China (Nos. 2 019YFC1005 200 and 2019YFC1005201), the Natural Science Foundation of Beijing (No. 7202213) and the National Natural Science Foundation of China (No. 82072861, 81672571, and 81874108).

REFERENCES

1. Verze P, Cai T, Lorenzetti S. The Role of the Prostate in Male Fertility, Health and Disease. Nat Rev Urol (2016) 13(7):379–86. doi: 10.1038/nruro.2016.89
2. Cutruzzolà F, Giardina G, Marani M, Macone A, Paiardini A, Rinaldo S, et al. Glucose Metabolism in the Progression of Prostate Cancer. Front Physiol (2017) 8:97. doi: 10.3389/fphys.2017.00097
3. Ward PS, Thompson CB. Metabolic Reprogramming: A Cancer Hallmark Even Warburg did Not Anticipate. Cancer Cell (2012) 21(3):297–308. doi: 10.1016/j.ccr.2012.02.014
4. Phillips SA, Thornalley PJ. The Formation of Methylglyoxal From Triose Phosphates. Investigation Using a Specific Assay for Methylglyoxal. Eur J Biochem (1993) 212(1):101–5. doi: 10.1111/j.1432-1323.1993.tb17638.x
5. Yumnam S, Subedi L, Kim SY. Glyoxalase System in the Progression of Skin Aging and Skin Malignancies. Int J Mol Sci (2020) 22(3):310. doi: 10.3390/ijms22030310
6. McElhan AC, Thornalley PJ, Benn J, Sonksen PH. Glyoxalase System in Clinical Diabetes Mellitus and Correlation With Diabetic Complications. Clin Sci (Lond) (1994) 87(1):21–9. doi: 10.1042/cs0870021
7. Fan X, David RS, Zhang J, Ina N, Mathilde T, Lu J, et al. Anaerobic vs Aerobic Pathways of Carbohydry and Oxidant Stress in Human Lens and Skin During Aging and in Diabetes: A Comparative Analysis. Free Radic Biol Med (2010) 49(5):847–56. doi: 10.1016/j.freeradbiomed.2010.06.003
8. Agalou S, Ahmed N, Babaei-Jadidi R, Dawny A, Thornalley PJ. Profound Mishandling of Protein Glycation Degradation Products in Uremia and Dialysis. J Am Soc Nephrol (2005) 16(5):1471–85. doi: 10.1681/ASN.2004080635
9. Thornalley PJ, Rabbani N. Glyoxalase in Tumourigenesis and Multidrug Resistance. Semin Cell Dev Biol (2011) 22(3):318–25. doi: 10.1016/j.semcdb.2011.02.006
10. Rabbani N, Thornalley PJ. Glyoxalase Centennial Conference: Introduction, History of Research on the Glyoxalase System and Future Prospects. Biochem Soc Trans (2014) 42(2):413–8. doi: 10.1042/BST20140014
11. Rabbani N, Xue M, Thornalley PJ. Dicarbonyls and Glyoxalase in Disease Mechanisms and Clinical Therapeutics. Glycoconj J (2016) 33(4):513–25. doi: 10.1007/s10719-016-9705-z
12. Richard JP. Mechanism for the Formation of Methylglyoxal From Triosephosphates. Biochem Soc Trans (1993) 21(2):549–53. doi: 10.1042/bst0210549
13. Pompliano DL, Peyman A, Knowles JR. Stabilization of a Reaction Intermediate as a Catalytic Device: Definition of the Functional Role of the Flexible Loop in Triosephosphate Isomerase. Biochemistry (1990) 29(13):3186–94. doi: 10.1021/bi00465a005
14. Baynes JW, Thorpe SR. Glycoxidation and Lipoxygenation in Atherogenesis. Free Radic Biol Med (2000) 28(12):1708–16. doi: 10.1016/S0891-5849(00)00228-8
15. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The Role of Lipid Peroxidation and Antioxidants in Oxidative Modification of LDL. Free Radic Biol Med (1992) 13(4):341–90. doi: 10.1016/0891-5849(92)90181-F
16. Ray M, Ray S. Aminoacetoate Oxidase From Goat Liver. Formation of Methylglyoxal From Aminoacetone. J Biol Chem (1987) 262(13):5974–7. doi: 10.1016/S0021-9258(18)35524-X
17. Reichard GAlr., Skutches CL, Hoeddeke RD, Owen OE. Acetone Metabolism in Humans During Diabetic Ketoadisis. Diabetes (1986) 35(6):668–74. doi: 10.2337/dbi.35.6.668
18. Chetrykin S, Mathis P, Pedchenko V, Sanchez OA, Hayes WM, Hachey DL, et al. Glucose Autoxidation Induces Functional Damage to Proteins via Modification of Critical Arginine Residues. Biochemistry (2011) 50 (27):6102–12. doi: 10.1021/b200757d
19. Giacco F, Brownlee M. Oxidative Stress and Diabetic Complications. Circ Res (2010) 107(9):1058–70. doi: 10.1161/CIRCRESAHA.110.223545
20. Veech RL, Rajman L, Dalziel K, Krebs HA. Disequilibrium in the Triose Phosphate Isomerase System in Rat Liver. Biochem J (1969) 115(4):837–42. doi: 10.1042/bj0490366
21. Nagao M, Fujita Y, Wakabayashi K, Nukaya H, Kosuge T, Sugimura T, et al. Glyoxalase I Modulation in Obesity and Diabetes. Antioxid Redox Signal (2010) 12(9):1311–20. doi: 10.1089/ars.2010.3993
22. Wang J, Chang T. Methylglyoxal Content in Drinking Coffee as a Cytotoxic Factor. J Food Sci (2010) 75(6):H167–71. doi: 10.1111/j.1750-3841.2010.01588.x
23. Degen J, Vogel M, Richter D, Hellwig M, Henle T. Metabolic Transit of Dietary Methylglyoxal. J Agric Food Chem (2013) 61(43):10253–60. doi: 10.1021/jf404946p
24. Zhang S, Liang X, Zheng X, Huang H, Chen X, Wu K, et al. Gluc Genetic Amplification as a Potential Therapeutic Target in Hepatocellular Carcinoma. Int J Clin Exp Pathol (2011) 4(5):797–90. doi: 10.4137/IJGEA.S8372
25. Rabbani N, Thornalley PJ. Glyoxalase 1 Modulation in Obesity and Diabetes. Antioxid Redox Signal (2010) 12(9):1311–20. doi: 10.1089/ars.2010.3993
26. Baba SP, Barski OA, Ahmed Y, O’Toole TE, Conklin DJ, Bhatnagar A, et al. Pharmacology of Methylglyoxal: Formation, Modification and Host Response. Biochem Pharmacol (2003) 65(5):709–15. doi: 10.1016/S0006-2952(02)01357-9
27. Wang J, Chang T. Methylglyoxal Content in Drinking Coffee as a Cytotoxic Factor. J Food Sci (2010) 75(6):H167–71. doi: 10.1111/j.1750-3841.2010.01588.x
28. Baba SP, Barski OA, Ahmed Y, O’Toole TE, Conklin DJ, Bhatnagar A, et al. Pharmacology of Methylglyoxal: Formation, Modification and Host Response. Biochem Pharmacol (2003) 65(5):709–15. doi: 10.1016/S0006-2952(02)01357-9
29. Rabbani N, Thornalley PJ. Glyoxalase 1 Modulation in Obesity and Diabetes. Antioxid Redox Signal (2010) 12(9):1311–20. doi: 10.1089/ars.2010.3993
30. Lederer MO, Klaiber RG. Cross-Linking of Proteins by Maillard Processes: Characterization and Detection of Lysine-Mannose-Amine Cross-Links Derived From Glyoxal, Methylglyoxal and Bovine Serum Albumin. Biochem Pharmacol (1999) 7(11):2499–507. doi: 10.1016/S0006-2952(99)00212-6
31. Westwood ME, Thornalley PJ. Molecular Characteristics of Methylglyoxal-Modified Bovine and Human Serum Albumins. Comparison With Glucose-Derived Advanced Glycation Endproduct-Modified Serum Albumins. J Proteom Chem (1995) 14(5):359–72. doi: 10.1007/BF01886793
32. Shipanova IN, Glomb MA, Nagaraj RH. Protein Modification by Methylglyoxal: Chemical Nature and Synthetic Mechanism of a Major Fluorescent Adduct. Arch Biochem Biophys (1997) 344(1):29–36. doi: 10.1006/abbi.1997.0195
33. Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T, et al. Methylglyoxal Modification of Protein. Chemical and Immunochemical Characterization of Methylglyoxal-Arginine Adducts. J Biol Chem (1999) 274(26):18492–502. doi: 10.1074/jbc.274.26.18492
34. Thornalley PJ. Glyoxalase System: New Developments Towards an Understanding of DNA Instability and Glyoxalase 1-Associated Tumour Multidrug Resistance. Biochem Pharmacol (2003) 65(5):709–15. doi: 10.1016/S0006-2952(02)01357-9
35. Westwood ME, Thornalley PJ. Molecular Characteristics of Methylglyoxal-Modified Bovine and Human Serum Albumins. Comparison With Glucose-Derived Advanced Glycation Endproduct-Modified Serum Albumins. J Proteom Chem (1995) 14(5):359–72. doi: 10.1007/BF01886793
36. Westwood ME, Thornalley PJ. Molecular Characteristics of Methylglyoxal-Modified Bovine and Human Serum Albumins. Comparison With Glucose-Derived Advanced Glycation Endproduct-Modified Serum Albumins. J Proteom Chem (1995) 14(5):359–72. doi: 10.1007/BF01886793
37. Misra K, Banerjee AB, Ray S, Ray M. Glyoxalase System: New Developments Towards an Understanding of DNA Instability and Glyoxalase 1-Associated Tumour Multidrug Resistance. Biochem Pharmacol (2003) 65(5):709–15. doi: 10.1016/S0006-2952(02)01357-9
38. Misra K, Banerjee AB, Ray S, Ray M. Glyoxalase System: New Developments Towards an Understanding of DNA Instability and Glyoxalase 1-Associated Tumour Multidrug Resistance. Biochem Pharmacol (2003) 65(5):709–15. doi: 10.1016/S0006-2952(02)01357-9
39. Misra K, Banerjee AB, Ray S, Ray M. Glyoxalase System: New Developments Towards an Understanding of DNA Instability and Glyoxalase 1-Associated Tumour Multidrug Resistance. Biochem Pharmacol (2003) 65(5):709–15. doi: 10.1016/S0006-2952(02)01357-9
60. Rounds L, Nagle RB, Muranyi A, Jandova J, Gill S, Vela E, et al. Glyoxalase 1

61. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, et al. Methylglyoxal-

62. Bellahcène A, Nokin MJ, Castronovo V, Schalkwijk C. Methylglyoxal-

63. Antognelli C, Palumbo I, Aristei C, Talesa VN. Glyoxalase I Inhibition

64. Xue M, Rabbani N, Momiji H, Imbasi P, Anwar MM, Kitteringham N, et al. Activity, Regulation, Copy Number and

65. MacLeod AK, Mahon MM, Plummer SM, Higgins LG, Penning TM, Igarashi K,

66. Richarme G, Abdallah J, Mathas N, Gautier V, Dairou J. Further

67. Cameron AD, Olin B, Ridderström M, Mannervik B, Jones TA. Crystal

68. Lee JY, Song J, Kwon K, Jang S, Kim C, Baek K, et al. Human DJ-1 and its

69. Liu GH, Qu J, Shen X. NF-KappaB/P65 Antagonizes Nrf2-ARE Pathway by

70. Rabbani N, Xue M, Thornalley PJ. Activity, Regulation, Copy Number and

71. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global Variation in Copy Number in the Human Genome. Nature (2006) 444 (7118):444–54. doi:10.1038/nature05329

72. Shafie A, Xue M, Thornalley PJ, Rabbani N. Copy Number Variation of

73. Santarius T, Bignell GR, Greenman CD, Widaa S, Chen L, Mahoney CL, et al. GLO1-A Novel Amplified Gene in Human Cancer. Genes Chromosomes Cancer (2010) 49(8):711–25. doi:10.1002/gcc.20784

74. Hosoda F, Arai Y, Okada N, Shimizu H, Miyamoto M, Kitagawa N, et al. Integrated Genomic and Functional Analyses Reveal Glyoxalase I as a Novel Metabolic Oncogene in Human Gastric Cancer. Oncogene (2015) 34 (9):1196–206. doi:10.1038/onc.2014.57

75. Thornalley PJ. The Glyoxalase System in Health and Disease. Mol Aspects Med (1993) 14(4):287–371. doi:10.1016/0999-2997(93)90002-U

76. Daiyasu H, Osaka K, Ishino Y, Toh H. Expansion of the Zinc Metallo-

77. Bito A, Haider M, Briza P, Strasser P, Breitenbach M. Heterologous Expression, Purification, and Kinetic Comparison of the Cytoplasmic and Mitochondrial Glyoxalase II Enzymes, Glo2p and Glo4p, From Saccharomyces Cerevisiae. Protein Expr Purif (1999) 17(3):456–64. doi:10.1006/prep.1999.1151

78. Cordell PA, Futers TS, Grant PJ, Pease RJ. The Human Hydroyxycyclulathione Hydrolyse (HAGH) Gene Encodes Both Cytosolic and Mitochondrial Forms of Glyoxalase II. J Biol Chem (2004) 279(27):26635–61. doi:10.1074/jbc.M403470200

79. Antognelli C, Frosini R, Santolla MF, Peirce MJ, Talesa MJ, Talsea VN. Oleuropein-

80. Bito A, Haider M, Briza P, Strasser P, Breitenbach M. Heterologous Expression, Purification, and Kinetic Comparison of the Cytoplasmic and Mitochondrial Glyoxalase II Enzymes, Glo2p and Glo4p, From Saccharomyces Cerevisiae. Protein Expr Purif (1999) 17(3):456–64. doi:10.1006/prep.1999.1151

81. Antognelli C, Talesa MJ. Glyoxalases in Urological Malignancies. Int J Mol Sci (2018) 19(2):415. doi:10.3390/ijms19020415

82. Antognelli C, Ferri I, Belletza G, Siccu P, Love HD, Talsea VN, et al. Glyoxalase 2 Drives Tumorigenesis in Human Prostate Cells in a Mechanism Involving Androgen Receptor and P53-21 Axis. Mol Carcinog (2017) 56(9):2122–6. doi:10.1002/mcc.22688

83. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68 (6):394–424. doi:10.3322/caac.21492

84. Xue M, Rabbani N, Momiji H, Imbasi P, Anwar MM, Kitteringham N, et al. Transcriptional Control of Glyoxalase 1 by Nrf2 Provides a Stress-

85. Bellohčéne A, Nokin MJ, Castronovo V, Schalkwijk C. Methylglyoxal-

86. Rounds L, Nagle RB, Muranyi A, Jandova J, Gill S, Vela E, et al. Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer. Cancer (Basel) (2021) 13 (14). doi:10.3390/cancers13143608

87. Trippodi N, Mason R, Humphrey SJ, Davies AF, Herberg JA, Trowsdale J, et al. Physical Map of Human 6p21.2-6p21.3: Region Flanking the Centromeric End of the Major Histocompatibility Complex. Genome Res (1998) 8(6):631–43. doi:10.1101/gr.6.6.631

88. MacLeod AK, Mahon MM, Plummer SM, Higgins LG, Penning TM, Igarashi K, et al. Characterization of the Cancer Chemopreventive Nrf2-Dependent Gene Battery in Human Keratinocytes: Demonstration That the KEAP1-NRF2 Pathway, and Not the BACH1-NRF2 Pathway, Controls Cytoprotection Against Electrophiles and Slightly as Well as Redox-Cycling Compounds. Carcinogenesis (2009) 30(9):1571–80. doi:10.1093/carcin/bgp176

89. Zhang M, Zhang C, Zhang L, Yang Q, Zhou S, Wen Q, et al. Nrf2 is a Potential Prognostic Marker and Promotes Proliferation and Invasion in Human Hepatocellular Carcinoma. BMC Cancer (2015) 15:531. doi:10.1186/s12885-015-1451-1

90. Antognelli C, Moretti S, Frosini R, Puxeddu E, Sidoni A, Talesa VN, et al. Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer. (2019) 8(6):547. doi:10.3390/cancers8060547

91. Nishimoto S, Koike S, Inoue N, Suzuki T, Ogawasara Y. Activation of Nrf2 Attenuates Carbonyl Stress Induced by Methylglyoxal in Human Neuroblastoma Cells: Increase in GSH Levels is a Critical Event for the Detoxification Mechanism. Biochem Biophys Res Commun (2017) 483 (2):874–9. doi:10.1016/j.bbrc.2017.01.024

92. Liu GH, Qu J, Shen X, NF-Kappab/P65 Antagonizes Nrf2-ARE Pathway by Depressing CBP From Nrf2 and Facilitating Recruitment of HDAC3 to MafK. Biochim Biophys Acta (2008) 1783(5):713–27. doi:10.1016/j.bbamcr.2008.01.002

93. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global Variation in Copy Number in the Human Genome. Nature (2006) 444 (7118):444–54. doi:10.1038/nature05329
Glyoxalase System in Women Cancer

91. Scheifele C, Zhu Q, Ignatov A, Kalinski T, Nas N. Glyoxalase I Expression Analysis by Immunohistochemistry in Breast Cancer. Pathol Res Pract (2020) 216(10):153257. doi: 10.1016/j.prp.2020.153257

92. Guo Y, Zhang Y, Yang X, Lu P, Yan X, Xiao F, et al. Effects of Methylglyoxal and Glyoxalase I Inhibition on Breast Cancer Cells Proliferation, Invasion, and Apoptosis Through Modulation of MAPKs, MMP9, and Bel-2. Cancer Biol Ther (2016) 17(2):169–80. doi: 10.1080/15384047.2015.1121346

93. Huchtenreuther A, Bigl M, Hemdan NY, Debebe T, Gauvin T, Birkenmeier G. Modulation of GLO1 Expression Affects Malignant Properties of Cells. Int J Mol Sci (2017) 18(12):2133. doi: 10.3390/ijms18122133

94. Davies GF, Roessler WJ, Juurlink BH, Harkness TA. Trogitazine Overcomes Doxorubicin-Resistance in Resistant K562 Leukemia Cells. Leuk Lymphoma (2005) 46(8):1199–206. doi: 10.1080/1042899050102555

95. Mann J. Natural Products in Cancer Chemotherapy: Past, Present and Future. Nat Rev Cancer (2002) 2(2):143–8. doi: 10.1038/nrc723

96. Schmidt B, Ferreira C, Passos CL, Silva JL, Fialho E. Resveratrol, Curcumin and Piperine Alter Human Glyoxalase I in MCF-7 Breast Cancer Cells. Int J Mol Sci (2020) 21(15):5244. doi: 10.3390/ijms21155244

97. Santel T, Pflug G, Hemdan NY, Schafer A, Hollenbach M, Buchold M, et al. Curcumin Inhibits Glyoxalase I: A Possible Link to its Anti-Inflammatory and Anti-Tumor Activity. PLoS One (2008) 3(10):e3508. doi: 10.1371/journal.pone.0003508

98. Meiyanto E, Putri H, Larasati YA, Utomo RY, Jenie RI, Ikawati M, et al. Anti-Proliferative and Anti-Metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation With ROS Generation. Adv Pharm Bull (2019) 9(3):445–52. doi: 10.15171/aphb.2019.053

99. Weigelt B, Peterse JL, van ’t Veer LJ. Breast Cancer Metastasis: Markers and Models. Nat Rev Cancer (2005) 5(8):591–602. doi: 10.1038/nrc1670

100. Nokin MJ, Durieux F, Peixoto P, Chiavarina B, Peulen O, Blomme A, et al. Methylglyoxal, a Glycolysis Side-Product, Induces Hsp90 Glycation and Drug Resistance Phenotype in Cancer Cells. Drug Resist Targets (2016) 20(1):21–30. doi: 10.2147/drtr.d73080

101. Nokin MJ, Bellier J, Durieux F, Peixoto P, Gaunitz F, Birkenmeier G, et al. Modulation of GLO1 Expression Affects Malignant Properties of Cells. Int J Mol Sci (2017) 17(22):8333. doi: 10.3390/ijms17122323

102. Santel T, Pflug G, Hemdan NY, Schafer A, Hollenbach M, Buchold M, et al. Curcumin Inhibits Glyoxalase I: A Possible Link to its Anti-Inflammatory and Anti-Tumor Activity. PLoS One (2008) 3(10):e3508. doi: 10.1371/journal.pone.0003508

103. Meiyanto E, Putri H, Larasati YA, Utomo RY, Jenie RI, Ikawati M, et al. Anti-Proliferative and Anti-Metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation With ROS Generation. Adv Pharm Bull (2019) 9(3):445–52. doi: 10.15171/aphb.2019.053

104. Weigelt B, Peterse JL, van ’t Veer LJ. Breast Cancer Metastasis: Markers and Models. Nat Rev Cancer (2005) 5(8):591–602. doi: 10.1038/nrc1670

105. Nokin MJ, Durieux F, Peixoto P, Chiavarina B, Peulen O, Blomme A, et al. Methylglyoxal, a Glycolysis Side-Product, Induces Hsp90 Glycation and Drug Resistance Phenotype in Cancer Cells. Drug Resist Targets (2016) 20(1):21–30. doi: 10.2147/drtr.d73080

106. Santel T, Pflug G, Hemdan NY, Schafer A, Hollenbach M, Buchold M, et al. Curcumin Inhibits Glyoxalase I: A Possible Link to its Anti-Inflammatory and Anti-Tumor Activity. PLoS One (2008) 3(10):e3508. doi: 10.1371/journal.pone.0003508

107. Meiyanto E, Putri H, Larasati YA, Utomo RY, Jenie RI, Ikawati M, et al. Anti-Proliferative and Anti-Metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation With ROS Generation. Adv Pharm Bull (2019) 9(3):445–52. doi: 10.15171/aphb.2019.053

108. Weigelt B, Peterse JL, van ’t Veer LJ. Breast Cancer Metastasis: Markers and Models. Nat Rev Cancer (2005) 5(8):591–602. doi: 10.1038/nrc1670

109. Nokin MJ, Durieux F, Peixoto P, Chiavarina B, Peulen O, Blomme A, et al. Methylglyoxal, a Glycolysis Side-Product, Induces Hsp90 Glycation and YAP-Mediated Tumor Growth and Metastasis. Elife (2016) 5:e19375. doi: 10.7554/eLife.19375

110. Nokin MJ, Bellier J, Durieux F, Peixoto P, Oudemans A, Gabriel M, et al. Methylglyoxal, a Glycolysis Metabolite, Triggers Metastasis Through MEK/ERK/SMAD1 Pathway Activation in Breast Cancer. Breast Cancer Res (2019) 21(1):11. doi: 10.1186/s13058-018-1095-7

111. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An Oncogenic „Based In vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer. Cell (2008) 135(5):852–64. doi: 10.1016/j.cell.2008.09.061

112. Nokin MJ, Durieux F, Bellier J, Peixoto P, Uchida K, Spiegel DA, et al. Horneretic Potential of Methylglyoxal, a Side-Product of Glycolysis, in Switching Tumours From Growth to Death. Sci Rep (2017) 7(1):11722. doi: 10.1038/srep11722

113. Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. National Report to the Nation on the Status of Cancer, Part I. National Cancer Institute. CA Cancer J Clin (2020) 126(10):2225–38. doi: 10.3322/caac.21590

114. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin (2020) 70(1):7–30. doi: 10.3322/caac.21590

115. Gordon JT, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin (2020) 70(1):7–30. doi: 10.3322/caac.21590

116. Hussen HO, Hassen H, Labetoulle J, Rostaing L, Bismuth H. A Novel Target for Breast Cancer Growth and Metastasis. Oncoscience (2016) 3(2):52–8. doi: 10.18632/oncoscience.294

117. Wang D, Li T, Ye G, Shen Z, Hu Y, Mou T, et al. Overexpression of the Receptor for Advanced Glycation Endproducts (RAGE) is Associated With Poor Prognosis in Gastric Cancer. PLoS One (2015) 10(4):e0122697. doi: 10.1371/journal.pone.0122697

118. Wangen K, Chihara Y, Takahashi T. Co-Expression of the Receptor for Advanced Glycation Endproducts and the Ligand Amphoterin A Closely With Metastasis of Colorectal Cancer. Oncol Rep (2003) 10(2):445–8. doi: 10.3892/or.10.2.445
130. Khorramdelazad H, Bagheri V, Hassanshahi G, Karami H, Moogooei M, Zeinali M, et al. S100A12 and RAGE Expression in Human Bladder Transitional Cell Carcinoma: A Role for the Ligand/RAGE Axis in Tumor Progression? Asian Pac J Cancer Prev (2015) 16(7):2725–9. doi: 10.7314/ APICP.2015.16.7.2725

131. Rahimi F, Karimi J, Goodarzi MT, Saidijam M, Khodadadi I, Razavi AN, et al. Overexpression of Receptor for Advanced Glycation End Products (RAGE) in Ovarian Cancer. Cancer biomark (2017) 18(1):61–8. doi: 10.3233/ CBR-160674

132. Poljiccani A, Filippovic N, Pusic TV, Soljic V, Caric A, Babic MS, et al. Expression Pattern of RAGE and IGF-1 in the Human Fetal Ovary and Ovarian Serous Carcinoma. Acta Histochem (2015) 117(4-5):468–76. doi: 10.1016/j.acthis.2015.01.004

133. Auersperg N, Wong AS, Williams KE, Auersperg N, Godwin AK, Zeppernick F, Meinhold-Heerlein I. The New FIGO Staging System for Ovarian Serous Carcinoma. Acta Histochem (2015) 127(5):423–8. doi: 10.1016/j.acthis.2015.01.004

134. Pimple SA, Mishra GA. Global Strategies for Cervical Cancer Prevention and Screening. Minerva Ginecol (2019) 71(4):313–20. doi: 10.23736/S0026-4784.19.04397-1

135. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, et al. Proteomic Analysis and Identification of New Biomarkers and Therapeutic Targets for Invasive Ovarian Cancer. Proteomics (2002) 2(1):76–84. doi: 10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.0.CO;2-O

136. Zeppernick F, Meinhold-Heerlein I. The New FIGO Staging System for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. Arch Gynecol Obstet (2015) 290(5):839–97. doi: 10.1007/s00404-014-3364-8

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Yang, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.